Wikisage, the free encyclopedia of the second generation, is digital heritage
Bezafibrate: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
([[) |
||
| Line 10: | Line 10: | ||
<ref>[http://www.impactjournals.com/oncotarget/misc/linkedout.php?pii=4528 Optimal drug regimens for primary biliary cirrhosis: a systematic review and network meta-analysis]</ref> | <ref>[http://www.impactjournals.com/oncotarget/misc/linkedout.php?pii=4528 Optimal drug regimens for primary biliary cirrhosis: a systematic review and network meta-analysis]</ref> | ||
ursodeoxycholic acid and bezafibrate are under study in the treatment of biliar | ursodeoxycholic acid and bezafibrate are under study in the treatment of [[biliar cirrhosis]] (See Figure in gallery). | ||
==Links== | ==Links== | ||
[http://www.scielo.br/pdf/ag/v51n3/0004-2803-ag-51-03-255.pdf Ginseng, green tea or fibrate: valid options for nonalcoholic steatohepatitis prevention?] | [http://www.scielo.br/pdf/ag/v51n3/0004-2803-ag-51-03-255.pdf Ginseng, green tea or fibrate: valid options for nonalcoholic steatohepatitis prevention?] | ||
Revision as of 15:19, 23 November 2015
Bezafibrate was originally developed as a drug for treatment of hyperlipidemia and used for the prevention of cardiovascular diseases. This fibrate reduces triglyceride and riseHDL-cholesterol[1][2]
ursodeoxycholic acid and bezafibrate are under study in the treatment of biliar cirrhosis (See Figure in gallery).
Links
Ginseng, green tea or fibrate: valid options for nonalcoholic steatohepatitis prevention?
ATC
Lipid modifying agents
- ↑ How Does Bezafibrate Affect the Plasma HDL Cholesterol Levels?
- ↑ Determinants of Bezafibrate-induced Improvements in LDL Cholesterol in Dyslipidemic Patients with Diabetes.
- ↑ Systematic review and meta-analysis: bezafibrate in patients with primary biliary cirrhosis
- ↑ Optimal drug regimens for primary biliary cirrhosis: a systematic review and network meta-analysis
- ↑ http://www.whocc.no/atc_ddd_index/?code=C10AB02
